A real world study in an adolescent and young adult inflammatory bowel disease (IBD) population found no significant differences in key laboratory markers or disease activity in patients who remained on the originator (Remicade) compared with those who switched to the biosimilar CT-P13 (Inflectra; infliximab-dyyb). Dosing regimens and the development of antidrug antibodies were also similar between groups over 1 year.
Image credit: Jo Panuwat D – stock.adobe.com
Prior to this study there was limited data on switching from the reference infliximab to biosimilars in pediatric patients with IBD, according to the authors. They wrote, “patients and families should be reassured of the safety of switching to a biosimilar.”
Tumor necrosis factor (TNF)-α inhibitors are indicated for treatment of adults and children with…